| 臺大學術典藏 |
2021-09-04T06:11:08Z |
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
|
Su T.-H.; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; Hsu S.-J.; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; Tseng T.-C.; Chen C.-L.; JIA-HORNG KAO; the C-TEAM study group; the Taiwan Liver Diseases Consortium |
| 臺大學術典藏 |
2021-09-04T06:11:03Z |
Elimination of Hepatitis B: Is It a Mission Possible?
|
Tseng T.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:01Z |
HBV markers for HCC prediction: Three heads are better than two?
|
Tseng T.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:01Z |
More viral mutants, less HBsAg clearance? One size may not fit all
|
Tseng T.-C.; Yang H.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:10:59Z |
Fibrosis-4 Index Helps Identify HBV Carriers with the Lowest Risk of Hepatocellular Carcinoma
|
Tseng T.-C.; Liu C.-J.; Su T.-H.; Yang W.-T.; Chen C.-L.; Yang H.-C.; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:10:59Z |
Impact of occult hepatitis B on the clinical outcomes of patients with chronic hepatitis C virus infection: A 10-year follow-up
|
Chen H.-Y.; Su T.-H.; Tseng T.-C.; Yang W.-T.; Chen T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO; Liu C.-J. |
| 臺大學術典藏 |
2021-09-04T06:10:55Z |
Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis
|
Su T.-H.; Shiau C.-W.; Jao P.; Yang N.-J.; Tai W.-T.; Liu C.-J.; Tseng T.-C.; Yang H.-C.; Liu C.-H.; Huang K.-W.; Hu T.-C.; Huang Y.-J.; Wu Y.-M.; Chen L.-J.; Chen P.-J.; Chen D.-S.; Chen K.-F.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:17:10Z |
Hepatitis b virus–specific t cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation
|
Rivino L.; Le Bert N.; Gill U.S.; Kunasegaran K.; Cheng Y.; Tan D.Z.M.; Becht E.; Hansi N.K.; Foster G.R.; Su T.-H.; Tseng T.-C.; Lim S.G.; JIA-HORNG KAO; Newell E.W.; Kennedy P.T.F.; Bertoletti A. |
| 臺大學術典藏 |
2021-09-04T05:17:09Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:17:08Z |
HCC risk in patients with HBV-related cirrhosis receiving nucleos(t)ide analogues therapy: Is HCC prevented or delayed?
|
Su T.-H.; Tseng T.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:17:08Z |
Distinct Relapse Rates and Risk Predictors after Discontinuing Tenofovir and Entecavir Therapy
|
Su T.-H.; Yang H.-C.; Tseng T.-C.; Liou J.-M.; Liu C.-H.; Chen C.-L.; Chen P.-J.; Chen D.-S.; Liu C.-J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:17:07Z |
Fibrosis-4 index predicts cirrhosis risk and liver-related mortality in 2075 patients with chronic HBV infection
|
Tseng T.-C.; Liu C.-J.; Su T.-H.; Yang W.-T.; Chen C.-L.; Yang H.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:17:06Z |
Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection
|
Liu C.-H.; Sun H.-Y.; Liu C.-J.; Sheng W.-H.; Hsieh S.-M.; Lo Y.-C.; Liu W.-C.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:17:05Z |
Acoustic radiation force impulse US imaging: Liver stiffness in patients with chronic hepatitis B with and without antiviral therapy
|
Su T.-H.; Liao C.-H.; Liu C.-H.; Huang K.-W.; Tseng T.-C.; Yang H.-C.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:17:03Z |
Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B
|
Tseng C.-H.; Hsu Y.-C.; Chang C.-Y.; Tseng T.-C.; Wu M.-S.; Lin J.-T.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:17:00Z |
Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study
|
Liu C.-H.; Huang Y.-J.; Yang S.-S.; Chang C.-H.; Yang S.-S.; Sun H.-Y.; Liu C.-J.; Liu W.-C.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:58Z |
A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment
|
Liu Y.-T.; Tseng T.-C.; Soong R.-S.; Peng C.-Y.; Cheng Y.-H.; Huang S.-F.; Chuang T.-H.; JIA-HORNG KAO; Huang L.-R. |
| 臺大學術典藏 |
2021-09-04T05:16:58Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:55Z |
Large and middle hepatitis B surface antigen: The lower the better?
|
Lin H.-H.; Tseng T.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:55Z |
Profile and value of FIB-4 in patients with dual chronic hepatitis C and B
|
Liu C.-J.; Tseng T.-C.; Yang W.-T.; Su T.-H.; Yang H.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:54Z |
Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection
|
Su T.-H.; Liu C.-J.; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; Chen P.-J.; Chen D.-S.; Chen C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:54Z |
Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis
|
Yeo Y.H.; Ho H.J.; Yang H.-I.; Tseng T.-C.; Hosaka T.; Trinh H.N.; Kwak M.-S.; Park Y.M.; Fung J.Y.Y.; Buti M.; Rodr?guez M.; Treeprasertsuk S.; Preda C.M.; Ungtrakul T.; Charatcharoenwitthaya P.; Li X.; Li J.; Zhang J.; Le M.H.; Wei B.; Zou B.; Le A.; Jeong D.; Chien N.; Kam L.; Lee C.-C.; Riveiro-Barciela M.; Istratescu D.; Sriprayoon T.; Chong Y.; Tanwandee T.; Kobayashi M.; Suzuki F.; Yuen M.-F.; Lee H.-S.; JIA-HORNG KAO; Lok A.S.; Wu C.-Y.; Nguyen M.H. |
| 臺大學術典藏 |
2021-09-04T05:16:53Z |
Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma
|
Su T.-H.; Liu C.-J.; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; Chen P.-J.; Chen D.-S.; Chen C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:48Z |
Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection
|
Liu C.-H.; Su T.-H.; Liu C.-J.; Hong C.-M.; Yang H.-C.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:46Z |
NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging
|
Su T.-H.; Liao S.-H.; Hong C.-M.; Liu C.-J.; Tseng T.-C.; Liu C.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chen C.-L.; Adhoute X.; Bourli?re M.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:45Z |
Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism
|
Su T.-H.; Yang H.-C.; Tseng T.-C.; Chou S.-W.; Lin C.-H.; Liu C.-H.; Liu C.-J.; Chen C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:45Z |
High Level of Hepatitis B Core–Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load
|
Tseng T.-C.; Liu C.-J.; Hsu C.-Y.; Hong C.-M.; Su T.-H.; Yang W.-T.; Chen C.-L.; Yang H.-C.; Huang Y.-T.; Fang-Tzu Kuo S.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:41Z |
Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis
|
Su T.-H.; Peng C.-Y.; Tseng T.-C.; Yang H.-C.; Liu C.-J.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:40Z |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan
|
Liu C.-H.; Liu C.-J.; Hung C.-C.; Hsieh S.-M.; Su T.-H.; Sun H.-Y.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:40Z |
Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients
|
Hsu S.-J.; Enkhzaya S.; Lin Y.-Y.; Tseng T.-C.; Khosbayar T.; Tsai C.-H.; Wang T.-S.; Enkhtuya D.; Ivshinkhorol D.; Naranzul N.; Jargalsaikhan B.; Amarsanaa J.; Baatarkhuu O.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:39Z |
Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy
|
Tseng T.-C.; Peng C.-Y.; Hsu Y.-C.; Su T.-H.; Wang C.-C.; Liu C.-J.; Yang H.-C.; Yang W.-T.; Lin C.-H.; Yu M.-L.; Lai H.-C.; Tanaka Y.; Nguyen M.H.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:38Z |
Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals
|
Liu C.-H.; Lee M.-H.; Lin J.-W.; Liu C.-J.; Su T.-H.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:37Z |
HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis
|
Tseng T.-C.; Liu C.-J.; Chang C.T.; Su T.-H.; Yang W.-T.; Tsai C.-H.; Chen C.-L.; Yang H.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:37Z |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment
|
Liu C.-H.; Yang S.-S.; Peng C.-Y.; Lin W.-T.; Liu C.-J.; Su T.-H.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:33Z |
Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer
|
Su T.-H.; Tseng T.-C.; Liu C.-J.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chen C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:30Z |
Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients
|
Yeo Y.H.; Tseng T.-C.; Hosaka T.; Cunningham C.; Fung J.Y.Y.; Ho H.J.; Kwak M.-S.; Trinh H.N.; Ungtrakul T.; Yu M.-L.; Kobayashi M.; Le A.K.; Henry L.; Li J.; Zhang J.; Sriprayoon T.; Jeong D.; Tanwandee T.; Gane E.; Cheung R.C.; Wu C.-Y.; Lok A.S.; Lee H.-S.; Suzuki F.; Yuen M.-F.; JIA-HORNG KAO; Yang H.-I.; Nguyen M.H. |
| 臺大學術典藏 |
2021-09-04T05:16:29Z |
Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan
|
Su H.-J.; JIA-HORNG KAO; Tseng T.-C.; Yang H.-C.; Su T.-H.; Chen P.-J.; Liu C.-J. |
| 臺大學術典藏 |
2021-09-04T05:16:27Z |
High risk of clinical relapse in patients with chronic Hepatitis B virus infection after cessation of prophylactic antiviral therapy for rituximab-containing chemotherapy
|
Chang W.-Y.; Chiu Y.-C.; Chiu F.-W.; Hsu Y.-C.; Tseng T.-C.; Cheng P.-N.; Yang S.-S.; Liu C.-J.; Su T.-H.; Yang H.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:23Z |
Letter: elevated HBV DNA predicts poor survival in hepatocellular carcinoma after hepatic resection—authors' reply
|
Tseng T.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:22Z |
APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients
|
JIA-HORNG KAO; Jeng W.-J.; Ning Q.; Su T.-H.; Tseng T.-C.; Ueno Y.; Yuen M.-F. |
| 臺大學術典藏 |
2021-09-04T05:16:21Z |
Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis
|
Su T.-H.; Peng C.-Y.; Chang S.-H.; Tseng T.-C.; Liu C.-J.; Chen C.-L.; Liu C.-H.; Yang H.-C.; Chen P.-J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:20Z |
Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients
|
Liu M.; Tseng T.-C.; Jun D.W.; Yeh M.-L.; Trinh H.; Wong G.L.H.; Chen C.-H.; Peng C.-Y.; Kim S.E.; Oh H.; Kwak M.-S.; Cheung M.; Toyoda H.; Hsu Y.-C.; Jeong J.Y.; Yoon E.L.; Ungtrakul T.; Zhang J.; Xie Q.; Ahn S.B.; Enomoto M.; Shim J.-J.; Cunningham C.; Jeong S.W.; Cho Y.K.; Ogawa E.; Huang R.; Lee D.-H.; Takahashi H.; Tsai P.-C.; Huang C.-F.; Dai C.-Y.; Tseng C.-H.; Yasuda S.; Kozuka R.; Li J.; Wong C.; Wong C.C.; Zhao C.; Hoang J.; Eguchi Y.; Wu C.; Tanaka Y.; Gane E.; Tanwandee T.; Cheung R.; Yuen M.-F.; Lee H.-S.; Yu M.-L.; JIA-HORNG KAO; Yang H.-I.; Nguyen M.H. |
| 臺大學術典藏 |
2021-09-04T05:16:20Z |
One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment
|
Tseng T.-C.; Choi J.; Nguyen M.H.; Peng C.-Y.; Siakavellas S.; Papatheodoridis G.; Wang C.-C.; Lim Y.-S.; Lai H.-C.; Trinh H.N.; Wong C.; Wong C.; Zhang J.; Li J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:18Z |
Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load
|
Tseng T.-C.; Liu C.-J.; Yang W.-T.; Hsu C.-Y.; Hong C.-M.; Su T.-H.; Tsai C.-H.; Chen C.-L.; Yang H.-C.; Liu C.-H.; Chen H.-H.; Chen P.-J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-08-20T07:38:56Z |
Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy
|
Liu C.-H.; Sun H.-Y.; SZU-MIN HSIEH; Liu W.-C.; Sheng W.-H.; Liu C.-J.; Su T.-H.; Tseng T.-C.; Chen P.-J.; Hung C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2021-08-20T07:10:54Z |
Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy
|
Liu C.-H.; HSIN-YUN SUN; Hsieh S.-M.; Liu W.-C.; Sheng W.-H.; Liu C.-J.; Su T.-H.; Tseng T.-C.; Chen P.-J.; Hung C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-12T02:44:50Z |
Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load
|
Tseng T.-C; | Liu C.-J; | HUNG-CHIH YANG; | Su T.-H; | Wang C.-C; | Chen C.-L; | Fang-Tzu Kuo S; | Liu C.-H; | Chen P.-J; | Chen D.-S; | Kao J.-H. |
| 臺大學術典藏 |
2021-07-12T02:44:50Z |
High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load
|
Tseng T.-C; | Liu C.-J; | HUNG-CHIH YANG; | Su T.-H; | Wang C.-C; | Chen C.-L; | Kuo S.F.-T; | Liu C.-H; | Chen P.-J; | Chen D.-S; | Kao J.-H. |
| 臺大學術典藏 |
2021-07-12T02:44:49Z |
Young chronic hepatitis b patients with nucleos(t)ide analogue-induced hepatitis b e antigen seroconversion have a higher risk of HBV reactivation
|
Tseng T.-C; | Liu C.-J; | Su T.-H; | HUNG-CHIH YANG; | Wang C.-C; | Chen C.-L; | Kuo S.F.-T; | Liu C.-H; | Chen P.-J; | Chen D.-S; | Kao J.-H. |
| 臺大學術典藏 |
2021-07-12T02:44:48Z |
Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads
|
Tseng T.-C; | Liu C.-J; | HUNG-CHIH YANG; | Su T.-H; | Wang C.-C; | Chen C.-L; | Hsu C.-A; | Fang-Tzu Kuo S; | Liu C.-H; | Chen P.-J; | Chen D.-S; | Kao J.-H. |
